The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

UBS Raises Tenet Healthcare Price Target to $288, Reaffirms "Buy" Rating

UBS recently re-affirmed its "Buy" rating for Tenet Healthcare (THC), signaling continued confidence in the company's performance. The investment bank significantly increased its price target for THC to $288, up from the previous $260. This positive adjustment aligns with generally optimistic sentiment from several other market analysts. However, GuruFocus's GF Value estimates a potential downside for THC, suggesting a divergence in valuation perspectives. The upward revision by UBS reflects strong optimism regarding Tenet Healthcare's future prospects, despite the presence of varied valuations.